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We report the molecular cloning of a proline/arginine-rich protein (called PARP) from human cartilage using the polymerase chain reaction (PCR) 
and degenerate oligonucleotides based on the previously published amino acid sequence of bovine PARP [l]. Subsequently, a reverse transcription- 
polymerase chain reaction (RT-PCR) was performed with poly(A)-rich RNA from human cartilage using a sense oligonucleotide derived from 
PARP and an anti-sense oligonucleotide derived from the known sequence of the human collagen a2(XI) chain [2]. Nucleotide sequencing of the 
PCR product demonstrated that PARP is a fragment of the NHz-terminal non-collagenous (NC3) domain of the collagen a2(XI) chain. 
Cartilage; Human collagen type XI; Polymerase chain reaction; Nucleotide sequence 
1. INTRODUCTION 2. MATERIALS AND METHODS 
In 1990, a proline/arginine-rich protein (called 
PARP) was isolated from bovine cartilage and the com- 
plete amino acid sequence determined [l]. PARP was 
found to be related to the NH,-terminal domain of sev- 
eral collagen types, being most closely related (49% 
identity) to the NH,-terminal domain of the collagen 
al(X1) chain [1,3,4]. We now report the molecular clon- 
ing of human PARP using RT-PCR performed with 
degenerate oligonucleotide primers designed from the 
published amino acid sequence of bovine PARP. A sub- 
sequent RT-PCR reaction was performed with a sense 
primer derived from human PARP and an anti-sense 
primer derived from the published nucleotide sequence 
of the human ol2(XII) collagen chain [2]. Cloning and 
nucleotide sequencing of the 1.86 kbp PCR product 
demonstrated that PARP is a fragment of the amino- 
terminal non-collagenous (NC3) domain of the collagen 
a2(XI) chain. 
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2.1. Isolution of RNA andfirst strand cDNA synthesis 
Chondrocytes were isolated from sternal cartilage obtained from an 
eight-year-old white female following corrective surgery for pectus 
excavatum. Minced cartilage was incubated in digestion medium 
(MEM, 5% L-glutamine, 2% antibioticlantimycotic containing 127 
U/ml collagenase (Worthington Biochemical Corp., CLSl) overnight 
at 37°C with shaking. Chondrocytes were freed from the matrix by 
repeated pipetting, filtered through lens paper, and centrifuged to a 
pellet. The cells were resuspended in MEM supplemental with 10% 
fetal bovine serum, washed three times with MEM and the pellet 
subsequently solubilized in 4.0 M guanidine isothiocyanate, 0.1 M 
Tris-HCI, pH 7.4, 0.1 M 2-mercaptoethanol and 0.5% N-lauryl-sar- 
cosine. Total RNA was obtained by the single step acid-guanidine 
method [5] and poly(A)-rich RNA selected by oligo(dT)-cellulose 
chromatography [6]. First strand cDNA for PCR analysis was pre- 
pared as described previously [7]. 
2.2. PCR conditions and cloning of PCR products 
Conditions for all PCR reactions were: denaturation, 92”C, 1 min; 
annealing, 58”C, 1 min; polymerization, 72”C, 3 min; for 30 cycles as 
described [7]. After agarose gel electrophoresis, individual bands were 
recovered using Geneclean (BIO 101, LaJolla, CA) as described [7]. 
To clone PARP, RT-PCR was performed using degenerate 20-mer 
oligonucleotides designed from the bovine amino acid sequence. Sense 
and antisense primers were: 5’-GGIACIGCICC(ACGT)GT(ACGT)- 
GA(CT)GT-3’ and S-C(GT)CCAICCICC(CT)TC(AG)CA(CT)TC- 
3’ (Primers 1 and 2; for the location of these primers see Fig. 1) in 
which redundancy was reduced by incorporation of inosine at several 
sites [8]. 
To obtain a PCR product bridging PARP and the a2(XI) chain the 
sense primer from PARP was 5’-CTCCTGACTCTCTACAGTGC-3’ 
(Primer 3; Fig. 1) and the antisense primer was 5’-CTGACGTCCAG- 
GATAGCCAG-3’ (Primer 4; positions 953-972 of the published nu- 
cleotide sequence [2]). 
Products of PCR were cloned into the pCRI1 vector using the TA 
Cloning kit as described by the manufacturer (Invitrogen, San Diego, 
CA). 
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Total amino acids/domain (from references 2.9-12). 
NC3 COL2 NC2 COLl NC1 
‘SP PARP VR CR’ 
cc2(xI) - 218 45 22 51 37 1014 190 
ccl(X1) 36 225 159 22 51 36 1014 264 
al(V) 36 225 185 22 51 39 1014 266 
SP = signal peptide; PARP = prolinekqinine rich peptide; VR = variable region; CR = constant region 
Fig. 2. A model for the organization of the domains and sub-domains of the a2(XI), cfl(X1) and al(V) chains. 
2.3. DNA sequencing 
Dideoxynucleotide sequencing was performed on either single or 
double stranded DNA obtained after cloning PCR products in the 
pCRI1 vector. For PARP clones, Sequenase 2.0 (US Biochemicals) 
was used and for PARP-a2(XI) bridging clones Taq polymerase was 
used (TAQuence 2.0, US Biochemicals). Nucleotide sequences of 
PARP were obtained from a single clone (NZl), and for PARP-ct2(XI) 
bridging clones two independent clones (called NZ2 and NZ3) were 
sequenced. 
3. RESULTS 
In order to clone PARP, RT-PCR was initially per- 
formed with degenerate primers designed from the pro- 
tein sequence of bovine PARP. The location of these 
primers (called Primer 1 and 2) and the nucleotide se- 
quence for a clone of the PCR product called NZl is 
shown in Fig. 1. Primer 1 was a degenerate primer 
designed from the amino terminal sequence of bovine 
PARP (GTAPVDV [ 11). However, subsequent nucleo- 
tide sequencing of NZl demonstrated that priming had 
occurred 24 amino acids further downstream at the se- 
quence GICPADV. 
To obtain a clone bridging between PARP and the 
a2(XI) chain, RT-PCR was performed using sense and 
anti-sense primers located at sites 3 and 4 in Fig. 1. The 
nucleotide sequence of this clone (called NZ2) is also 
shown in Fig. 1, together with a comparison of the 
derived protein sequence of human PARP with bovine 
PARP. Close agreement was observed with 17 largely 
conservative differences, demonstrating the successful 
cloning of human PARP. In addition, complete agree- 
ment was found for the nucleotide sequence at the 3’ end 
of NZ2 with the published nucleotide sequence of 
human cl2(XI) in the same region [2]. This result there- 
fore establishes that PARP is derived from the amino- 
terminal non-collagenous (NC3) domain of the a2(XI) 
chain. 
With the sequence of the amino terminus of the 
a2(XI) chain (Fig. 1) and the complete sequences of the 
cll(X1) and al(V) chains now available [9,10-121, it is 
possible to recognize several different domains and a 
model labeling these structures is shown in Fig. 2. In the 
same manner as several other collagens. the domains 
are numbered from the 3’ end so that the major col- 
lagenous domain is designated COLl. A second shorter 
collagenous domain is labeled COL2 and the NC3 do- 
main is further subdivided into four subdomains. In 
several previous studies homologies between the se- 
quence of PARP and the al(XI),oll(V),al(IX),crl(XII), 
and al(XIV) chains were noted suggesting a common 
ancestral origin for this structure [1,3,4]. 
The NC3-PARP subdomain is followed by the NC3- 
variable region (NC3-VR) which is much shorter for 
cr2(XI) than for oll(X1) and al(V) (Fig. 2). Previous 
comparison of this region for the cxl(X1) and al(V) 
chains showed very little homology [ 121, and this region 
Fig. 1. The nucleotide sequence and deduced amino sequence of PCR-derived clones NZI and NZ2 which bridge from PARP to the COLl domain 
of 1x2(X1). Sites I and 2 are the location of degenerate primers used initially to obtain clone NZl. Sites 3 and 4 represent the location of primers 
used to obtain clone NZ2 which bridges from PARP to a2(XI). The collagenous domains COLl and COL2 are shown by boxed sequences between 
which is the NC2 domain. The carboxyl-terminus of PARP is designated by, and differences between the amino acid sequence of bovine and human 
PARP are shown on the third line for this sub-domain. The sequence from * to l represents the variable region of the NC3 domain (VR-NC3) 
and the short sequence after l to COL2 represents the constant region of NC3 (CR-NC3). The conserved crosslinking site (KGHR) in COLl is 
indicated by A. The start of the published nucleotide sequence of the human aZ(X1) chain is indicated by t. 
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for a2(XI) did not appear closely related to either the 
orl(X1) or al(V) sequences. The remaining NC3-con- 
stant region (NC3-CR), COL2, NC2 and COLI do- 
mains all showed a high degree of homology between 
the a2(XI), crl(X1) and al(V) chains. 
4. DISCUSSION 
The successful cloning of human PARP and its origin 
from the a2(XI) chain allow a comparison to be made 
with other chains of the type V/type XI family. The 
results show close homologies with the ol2(XI) and 
al(V) chains but marked differences from the c12(V) 
chain as noted previously [ 131. However, at one subdo- 
main (called NC3-VR) marked differences were ob- 
served for the 012(X1), al(X1) and al(V) chains both in 
length and in deduced amino acid sequence. This do- 
main is, however, acidic for all three chains and does 
not contain cysteine residues. It appears that the NC3 
domain may form an extended structure that cannot be 
visualized after rotary shadowing [14]. With the availa- 
bility of the amino-terminal sequences of the aI and 
ol2(XI) chains, it will now be possible to analyze the 
processing events that occur before the final tissue 
forms of these chains are achieved [14]. 
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